NOS3 and endothelial dysfunction: In addition, high levels of endothelial nitric oxide synthase (eNOS) inhibitor asymmetric dimethylarginine (ADMA) in plasma have been linked to an increased risk for endothelial dysfunction associated with cognitive decline [14,15].